[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2002214624A1 - Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150 - Google Patents

Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150

Info

Publication number
AU2002214624A1
AU2002214624A1 AU2002214624A AU1462402A AU2002214624A1 AU 2002214624 A1 AU2002214624 A1 AU 2002214624A1 AU 2002214624 A AU2002214624 A AU 2002214624A AU 1462402 A AU1462402 A AU 1462402A AU 2002214624 A1 AU2002214624 A1 AU 2002214624A1
Authority
AU
Australia
Prior art keywords
human cytomegalovirus
ctl epitopes
hcmv
immunoreactive peptide
peptide ctl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214624A
Inventor
Don J. Diamond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of AU2002214624A1 publication Critical patent/AU2002214624A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/4611—
    • A61K39/464838—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides peptides which are immunogenic epitopes recognized by CD8+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent cytomegalovirus (HCMV) infection. The peptides are capable of activating CTL in the absence of active viral replication, and thus are useful for eliciting a cellular immune response against HCMV by normal and immunodeficient subjects. Vaccines against HCMV, with and without adjuvants, and immunological and diagnostic reagents are disclosed.
AU2002214624A 2000-10-20 2001-10-22 Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150 Abandoned AU2002214624A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24194400P 2000-10-20 2000-10-20
US60/241,944 2000-10-20
PCT/US2001/032589 WO2002034769A2 (en) 2000-10-20 2001-10-22 Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150

Publications (1)

Publication Number Publication Date
AU2002214624A1 true AU2002214624A1 (en) 2002-05-06

Family

ID=22912827

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002214624A Abandoned AU2002214624A1 (en) 2000-10-20 2001-10-22 Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150

Country Status (8)

Country Link
US (1) US6544521B2 (en)
EP (1) EP1328540B1 (en)
JP (1) JP4099058B2 (en)
AT (1) ATE291584T1 (en)
AU (1) AU2002214624A1 (en)
CA (1) CA2425202C (en)
DE (1) DE60109633T2 (en)
WO (1) WO2002034769A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171028A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US6632435B1 (en) * 1999-10-20 2003-10-14 City Of Hope CTL epitope analogs
US20040101534A1 (en) * 2002-06-25 2004-05-27 Diamond Don J. Adjuvant-free peptide vaccine
US7163685B2 (en) 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
US20050232933A1 (en) * 2003-09-30 2005-10-20 Zaia John A CMV-IE1 peptides and method of use
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
CN1325649C (en) * 2005-08-11 2007-07-11 山东省医药生物技术研究中心 Gene recombinant human cytomegalovirus fusion protein pp150/MDBP, preparation process and application thereof
US20080138354A1 (en) * 2006-07-21 2008-06-12 City Of Hope Cytomegalovirus vaccine
AU2016270823B2 (en) 2015-06-01 2020-09-03 California Institute Of Technology Compositions and methods for screening T cells with antigens for specific populations
WO2016209816A1 (en) 2015-06-26 2016-12-29 Memorial Sloan Kettering Cancer Center Methods of treating cmv retinitis by t cell therapy
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN110699318A (en) * 2018-07-09 2020-01-17 广西慧宝源健康产业有限公司 T cell culture medium and culture method
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TW202413391A (en) 2020-06-21 2024-04-01 美商輝瑞股份有限公司 Human cytomegalovirus gb polypeptide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075213A (en) 1984-07-27 1991-12-24 City Of Hope Method for detection and prevention of human cytomegalovirus infection
DE3782867D1 (en) * 1986-06-12 1993-01-14 Behringwerke Ag, 3550 Marburg, De Human cytomegalovirus phospho-protein
CA2092548A1 (en) 1990-09-28 1992-03-29 Philip D. Greenberg Method for producing th-independent cytotoxic t lymphocytes
US5470730A (en) 1990-09-28 1995-11-28 Immunex Method for producing TH -independent cytotoxic T lymphocytes
DE69232265T2 (en) 1992-06-25 2002-08-08 City Of Hope, Duarte INDUCTION OF CYTOLYTIC T-LYMPHOCYTEN WITH POLYPEPTIDES OF THE CYTOMEGALIEVIRUS
US5405940A (en) 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US6448389B1 (en) 1996-04-23 2002-09-10 The Wistar Institute Of Anatomy And Biology Human cytomegalovirus DNA constructs and uses therefor
AU735981B2 (en) * 1996-07-12 2001-07-19 Akzo Nobel N.V. Peptide reagent for the detection of human cytomegalovirus (CMV)
US6156317A (en) 1996-11-12 2000-12-05 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
FR2757169B1 (en) 1996-12-13 1999-03-05 Inst Nat Sante Rech Med FUSION PROTEIN COMPRISING ALL OR PART OF THE PP65 PROTEIN OF HUMAN CMV, ESPECIALLY USEFUL IN THE PREPARATION OF A VACCINE
JP2003501076A (en) 1999-06-04 2003-01-14 フロリアン・ケルン Peptides for vaccination against human CMV

Also Published As

Publication number Publication date
CA2425202C (en) 2012-01-03
WO2002034769A2 (en) 2002-05-02
US20020146820A1 (en) 2002-10-10
DE60109633T2 (en) 2006-01-19
DE60109633D1 (en) 2005-04-28
US6544521B2 (en) 2003-04-08
EP1328540A2 (en) 2003-07-23
JP2004512039A (en) 2004-04-22
ATE291584T1 (en) 2005-04-15
EP1328540B1 (en) 2005-03-23
CA2425202A1 (en) 2002-05-02
WO2002034769A3 (en) 2003-01-16
JP4099058B2 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
WO2001072782A3 (en) Immuno-reactive peptide CTL epitopes of human cytomegalovirus
AU7481498A (en) Immuno-reactive peptide ctl epitopes of human cytomegalovirus
AU2002214624A1 (en) Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150
WO1998021233A3 (en) Immuno-reactive peptide ctl epitopes of human cytomegalovirus
FI955667A0 (en) Adjuvants for RS virus vaccines
WO2008026225A3 (en) A vaccine for chikungunya virus infection
EP1698347A3 (en) hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination
WO2006031264A3 (en) Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
EP1451329A4 (en) Genetic vaccine against human immunodeficiency virus
DK1276896T3 (en) Epitope synchronization in antigen-presenting cells
NZ510544A (en) Novel adjuvant for subunit or component vaccines
AP2000001841A0 (en) Method for obtaining vaccines for preventing the pathgenic effects related to a retroviral infection.
EP1220925B8 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
HUP9901039A2 (en) Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines
EP0327305A3 (en) Preparation of a recombinant subunit vaccine against pseudorabies infection
CA2523084A1 (en) Tuberculosis vaccine with improved efficacy
WO2002068654A3 (en) Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
Fomsgaard HIV-1 DNA vaccines
EP1612217A3 (en) Immuno-reactive peptide CTL epitopes of human cytomegalovirus
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
Stahl-Hennig et al. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
Choi et al. Enhancement of DNA vaccine-induced immune responses by influenza virus NP gene
EP0250128A3 (en) Novel virus isolated from patients with aids
WOLF et al. HIV VACCINES: STATUS AND FUTURE
WO2024086380A3 (en) Recombinant protein vaccines formulated with enantio-specific cationic lipid r-dotap and methods of use thereof